HansBiomed Corporation (KOSDAQ:042520)

Market Cap	548.08B +364.3%
Revenue (ttm)	89.78B +10.7%
Net Income	-31.34B
EPS	-2,413.29
Shares Out	13.70M
PE Ratio	n/a
Forward PE	39.60
Dividend	n/a
Ex-Dividend Date	n/a

Volume	368,165
Average Volume	351,735
Open	42,500
Previous Close	43,900
Day's Range	37,750 - 43,000
52-Week Range	6,180 - 47,750
Beta	2.31
RSI	65.76
Earnings Date	Feb 12, 2026

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 277
• Stock Exchange: KOSDAQ
• Ticker Symbol: 042520

Financial Performance

In fiscal year 2025, HansBiomed's revenue was 89.78 billion, an increase of 10.65% compared to the previous year's 81.14 billion. Losses were -31.34 billion, 333.9% more than in 2024.